-
Article
Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?
Angiogenesis plays a key role in glioblastoma, but most anti-angiogenic therapy trials have failed to change the poor outcome of this disease. Despite this, and because bevacizumab is known to alleviate sympto...
-
Article
Open AccessNeoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
At diagnosis, tumor-infiltrating lymphocytes (TILs) are prognostic in epithelial ovarian cancer (EOC). We recently demonstrated that neoadjuvant chemotherapy (NACT) significantly increased stromal TILs. Here,...
-
Article
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens
HER2-negative metastatic breast cancer (MBC) is a common setting in which chemotherapy could be effective even in later lines of treatment. Oral etoposide has demonstrated clinical activity in this setting in ...
-
Article
Open AccessThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging activity in preclinical mode...
